For seven years, Noah Weiner, his brother, and their team built a clinical decision support platform that sent real-time recommendations to physicians the moment their actions deviated from best practice, directly inside their EMR.

By the time AmalgamRx acquired them in 2021, Avhana had direct integrations with every major EMR on the market: Epic, Cerner, Allscripts, athena, Greenway. Roughly 180 sites of care. They built each integration from scratch, before FHIR existed, before there were shortcuts.

Then, mid-raise for their Series A, during COVID, they got an offer at a multiple founders rarely see.

Five years into the company, Avhana was growing but had not reached escape velocity. Noah estimates that roughly 40% of Avhana's life was spent not knowing if the next payroll would clear.

Where they were winning was their EMR integrations, a capability that was difficult to build and harder to replicate. That made the first buyer come calling.

The offer was strong, and Noah felt confident. Confident enough to put an offer on a house, contingent on the sale closing. Then the buyer added a requirement for personal liability on future lawsuits. Noah and his brother walked away. The offer fell through, the house loan was pulled. The team went heads-down on growth.

A few months later, with three months of runway left, Avhana closed two six-figure contracts and secured a $250K angel investment in December 2019. The tide had turned.

Noah and the CEO of AmalgamRx had known each other for years. They went to the same college (though at different times) but had never crossed paths until an industry event years later. The CEO would call occasionally with EMR questions. Noah would chat with him about growth. Nothing that looked like a deal until it was.

Avhana had kept the business moving through COVID. More deals signed, more integrations built. The venture market was frothy, and Noah had enough traction to take the company out for a Series A. Relationship-driven revenue and a sticky product.

Then, mid-fundraise, the offer came in from AmalgamRx.

Noah's father-in-law told him a line that stuck: “Sell them the sizzle, not the steak.”

Revenue was not the acquisition story at Avhana. The strategic value came from two things that didn't show up on a P&L: a network of physician and health system relationships, and custom-built EMR integrations that were difficult to replicate.

Noah took the offer to two other potential buyers to see if anyone would move. Neither came close. AmalgamRx's offer was stronger, cleaner, and both sides saw the logic in moving forward.

At the time of acquisition, AmalgamRx's CEO Ryan Sysko publicly called EMR integration “The Holy Grail for digital health solutions” and was explicit that workflow optimization, not data integration, was the real prize. Their stated plan was to expand Avhana's tools across multiple therapeutic areas. They were acquiring a platform to run their existing business through, not a product. Each of these capabilities would have taken AmalgamRx years to build.

This was AmalgamRx's first acquisition. They had identified EMR-native clinical decision support as a gap worth buying rather than building. That alone drove the price, not the revenue.

The deal closed in 3 months.

AmalgamRx's offer was a mixture of cash, stock, and an earnout tied to milestones. The upfront cash alone exceeded everything Avhana had raised to that point. The deal also qualified for QSBS, which meaningfully reduced the tax hit for Noah and his shareholders.

But the most important part of the deal wasn't the price. Noah has a saying: even if you do not win, just don't lose. Noah negotiated for AmalgamRx to cover Avhana's burn during the exclusivity period. If the deal closed, the amount would be credited against the purchase price. If it fell apart, it would convert to a convertible note.

This was significant. Any founder who has been through this experience knows that the exclusivity period is the most dangerous point of an exit. The founder has stopped fundraising, stopped talking to other buyers, has no time for growth, and has handed the acquirer time and leverage. Deals die at this point regularly, with founders coming out the other side with depleted runway and nothing to show for that period.

The burn coverage meant that if the deal fell apart, Noah was not starting from zero.

The Avhana acquisition moved quickly. Three months from offer to close is fast. But the deal almost fell apart when a minority shareholder refused to sign. They had no formal blocking right. But the attorney recommended getting written signoff from every shareholder before closing, which is standard practice. This shareholder believed the exit was too small, that it would not be enough of a win for them.

A standard process handed a small stakeholder unexpected leverage at exactly the wrong moment.

Noah's rule now: equity goes to people who invested capital or showed up every day. Everyone else can invest, usually on good terms, but they do not get free ownership.

Most founders stay on after the deal closes. In Noah's case that was always the plan. The earnout required it, and AmalgamRx was buying the team as much as the technology.

But the earnout became a point of friction.

Earnouts exist to bridge a valuation gap. The seller thinks the business is worth more than the buyer will pay today, so the difference gets structured as future payments tied to performance. The theory is alignment. The reality is that once the deal closes, the acquirer runs the business for their shareholders. The founder runs it for the earnout. Those two incentives are not always compatible.

In Avhana's case, it came down to how certain metrics were defined. Neither side was wrong. The definition had not been nailed down at signing. That gap, which looked minor on paper, became a disagreement.

Noah's next company looks different by design. Today, he is building Robinhood Health, a virtual doctor's office for Medicaid patients, with a different approach to capital: angel and micro-VC funding, SBIR grants, and public programs like the Rural Health Transformation Program. The goal is to grow without handing over the control and timeline that institutional venture typically demands.

Healthcare does not move on a fund's schedule. He learned that the first time.

Exit outcomes are largely shaped before a buyer appears. They are defined by the relationships you have maintained, the capital decisions you have made, and the language you did or did not nail down in documents that felt hypothetical at the time.

The deal's headline number matters. But the lasting impact lies in the details you addressed early, or did not.

Acquirers in healthcare typically pay 4–8x revenue. VCs pitch 10–15x. If a real number lands on the table, take it seriously.

I used to think the deal was the outcome. Now I think the deal just reveals the decisions you already made.